The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Trial to Evaluate the Combination of Iressa & Faslodex® in Patients With Advanced or Metastatic Breast Cancer
Official Title: A Phase II Trial to Evaluate the Combination of ZD1839 (Iressa) and Fulvestrant (Faslodex®) in Patients With Advanced or Metastatic Breast Cancer
Study ID: NCT00234403
Brief Summary: The progression free survival and efficacy of 250 mg ZD1839 in combination with a fixed dose of fulvestrant 250 mg im once a month will be evaluated in female patients with histologically-confirmed advanced or metastatic, ER and/or PR positive breast cancer
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Investigative Site, Alicante, , Spain
Investigative Site, Gerona, , Spain
Investigative Site, Jaen, , Spain
Investigative Site, Madrid, , Spain
Investigative Site, Seville, , Spain
Investigative Site, Valencia, , Spain
Investigative Site, Zaragoza, , Spain
Name: AstraZeneca Spain Medical Director, MD
Affiliation: AstraZeneca
Role: STUDY_DIRECTOR